IOS-3933(IOS-3933) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

心血管疾病

在研适应症-

非在研适应症

血栓栓塞

原研机构

Russian Academy of Medical Sciences

在研机构-

非在研机构

Russian Academy of Medical Sciences

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 IOS-3933 相关的临床结果

登录后查看更多信息

100 项与 IOS-3933 相关的转化医学

登录后查看更多信息

100 项与 IOS-3933 相关的专利（医药）

登录后查看更多信息

2

项与 IOS-3933 相关的文献（医药）

Eksperimental'naia i klinicheskaia farmakologiia

Vliianie novykh sinteticheskikh prostanoidov na nekotorye pokazateli svertyvaiushcheĭ sistemy krovi.

Article

作者: Makarov, V A ; Sirotenko, A V ; Freĭmanis, Ia F ; Lozha, E V ; Petrukhina, G N

In the experiments on rabbits it was shown, that the administration of prostanoids IOS 3933 caused a reduction of ADP- and collagen induced platelet aggregation, platelet adhesion to collagen and elevation of t-PA level. This prostanoid prevented both a decrease in platelet count and reduction of AT III activity, but did not affect the protein C level during thromboplastin infusion.

Eksperimental'naia i klinicheskaia farmakologiia

[The effect of new synthetic prostanoids on the aggregation activity of human thrombocytes].

Article

作者: FReĭmanis, Ia F ; Makarova, V A ; Lozha, E V ; Petrukhina, G N

We found that a number of new synthetic prostanoids caused a prominent reduction of human platelet aggregation in the in vitro experiments. Moreover, two of this agents, IOS 3933 and IOS 4732, gives storage stability. Hemoxygenase activity, metabolic homeostasis of bilirubin in brain and transport function of serum albumin in animals receiving cobalt chloride.

100 项与 IOS-3933 相关的药物交易

登录后查看更多信息